Log in
NASDAQ:TCON

TRACON Pharmaceuticals Stock Forecast, Price & News

$8.89
-0.26 (-2.84 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.52
Now: $8.89
$9.84
50-Day Range
$4.38
MA: $6.55
$10.04
52-Week Range
$0.95
Now: $8.89
$10.65
Volume854,653 shs
Average Volume828,125 shs
Market Capitalization$121.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
TRACON Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780
Employees19

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$0.67 per share

Profitability

Net Income$-22,670,000.00

Miscellaneous

Market Cap$121.66 million
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
$8.89
-0.26 (-2.84 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

How has TRACON Pharmaceuticals' stock been impacted by Coronavirus?

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TCON stock has increased by 530.5% and is now trading at $8.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TRACON Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TRACON Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than TRACON Pharmaceuticals?

Wall Street analysts have given TRACON Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TRACON Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for TRACON Pharmaceuticals
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27.
View TRACON Pharmaceuticals' earnings history
.

What price target have analysts set for TCON?

1 Wall Street analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their forecasts range from $12.00 to $12.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 35.0% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals
.

Who are some of TRACON Pharmaceuticals' key competitors?

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:
  • Dr. Charles P. Theuer, CEO, Pres & Director (Age 56, Pay $826.76k)
  • Mr. Scott B. Brown CPA, M.S., Chief Accounting Officer & Head of Fin. (Age 39, Pay $445.04k)
  • Mr. Mark C. Wiggins M.B.A., Chief Bus. Officer (Age 64, Pay $501.84k)
  • Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 43)
  • Mr. Shahe Garabedian, Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo, Chief Medical Officer (Age 65)

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Boothbay Fund Management LLC (1.73%), GSA Capital Partners LLP (0.60%), Jane Street Group LLC (0.28%), Dowling & Yahnke LLC (0.26%), Vigilare Wealth Management (0.15%) and We Are One Seven LLC (0.14%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc and Saundra L Pelletier.
View institutional ownership trends for TRACON Pharmaceuticals
.

Which institutional investors are buying TRACON Pharmaceuticals stock?

TCON stock was acquired by a variety of institutional investors in the last quarter, including Boothbay Fund Management LLC, GSA Capital Partners LLP, Jane Street Group LLC, Vigilare Wealth Management, We Are One Seven LLC, Lindbrook Capital LLC, and Dowling & Yahnke LLC. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, and Saundra L Pelletier.
View insider buying and selling activity for TRACON Pharmaceuticals
.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $8.89.

How big of a company is TRACON Pharmaceuticals?

TRACON Pharmaceuticals has a market capitalization of $121.66 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-22,670,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis. TRACON Pharmaceuticals employs 19 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.